. Binding curve for STAT5a in a fluorescence polarization assay. STAT5a was incubated at room temperature in assay buffer at the indicated concentrations for 1 h to mimic the incubation period with test compounds. Subsequently, the fluorophore-labeled peptide 5-carboxyfluorescein-GY(PO3H2)LVLDKW was added (final concentration: 10 nM), and fluorescence polarization measured immediately (t = 1 h, solid circles) or after an additional hour (t = 2 h, empty circles). Both curves are essentially identical, indicating temporal stability of the assay. 636, 639, 640, 644, 664 , and 679 are shown. The side chains of Arg618 and Trp641, which are identical in both STAT5 proteins, are also shown to indicate the location of the binding pocket for 1. B) STAT5a SH2 domain as reported in the Xray structure (PDB 1Y1U) [1] . The side chains of amino acids at positions 636, 639, 640, 644, 664, and 679 are shown, together with the side chains of Arg618 and Trp641. C) Overlay of A) and B). STAT5b is depicted in yellow, STAT5a in lightblue. The numbering of the divergent amino acids was omitted for clarity of presentation. D) Overlay of A) and B) as shown in C), but amino acid side chains and numberings are omitted for clarity of depiction. Amino acids positions 636-640, which diverge in secondary structure, are highlighted (STAT5b: green; STAT5a: magenta).
Figure S4
Figure S4. Docking of compounds 7 and 9 into the STAT5b SH2 domain. The amide bond of compound 9 is directed towards the protein, suggesting the possibility of hydrogen bonding with the protein backbone at positions 642 and 644. In contrast, the amide bond of 7 is orientated parallel to the protein backbone, which make hydrogen bonds less likely. 
Scheme S1
Scheme S1. Natural-product inspired synthesis of catechol bisphosphate derivatives 4-8.
Scheme S2
Scheme S2. Synthesis of the BODIPY-FL-labeled catechol bisphosphate derivative 10. 17 -7 ± 4% inhibition at 100 µM n/a n/d n/d
n/a = not applicable; n/d: not determined. Lck SH2 38 ± 7 % inhibition at 100 µM n/a n/a: not applicable Table S2 . Activities of catechol bisphosphate (1) in binding assays based on fluorescence polarization. Lck SH2 33 ± 3 % inhibition at 40 µM n/a n/a: not applicable Table S3 . Activities of Stafib-1 (13) in binding assays based on fluorescence polarization. Table S4 . Activities of control compounds expected to display three (SI-1) or two (SI-2 to SI-5) negative charges at neutral pH, against STAT5b and STAT5a as analyzed in fluorescence polarization assays.
Supporting methods

Plasmid construction and protein expression
Cloning and expression, and purification protocols for STAT1, STAT3, STAT4, STAT5b, STAT6 and the Lck SH2 domain, have been described previously. [2] STAT5a amino acids 137-707 were amplified via PCR and cloned into a modified pQE70 vector carrying a C-terminal 6xHis-tag and an N-terminal maltose-binding protein (MBP) tag. Proteins were expressed from Rosetta BL21DE3 (Novagen) as previously published, and purified via the His-tag on Ni-ion exchange resin. After dialysis against a buffer containing 100 mM NaCl, 50 mM Hepes (pH 7.5), 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, and 0.1% Nonidet P40, protein concentration was determined via a BCA protein assay (Pierce) and aliquots were snap-frozen in liquid nitrogen and stored at -80 ºC until use.
Fluorescence polarization assays
For competition-based fluorescence polarization assays, the ability of the test compounds to displace fluorophore-labeled peptides from their respective binding proteins was analyzed. (K d -values) for the individual protein-peptide interactions in assay buffer. Inhibition curves were determined by incubating protein with test compounds for 60 min, followed by addition of the fluorophore-labeled peptides. Fluorescence polarization was analyzed after another 60 min using an Infinite F500 plate reader (Tecan). Stocks of fluorophore-labeled peptides or compound 10, and protein were diluted in assay buffer, which contains 10 mM Tris (pH 8.0), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 % Nonidet P-40 substitute, and 2 % DMSO in water. Assays were performed in black 384-well microtiter plates (Corning no. 3573). Percent inhibition was calculated based on curve fits using SigmaPlot (SPSS Science Software). IC 50 data were converted to K i -values using the published equation. [3] For the direct binding assays shown in Figure 2 , the BODIPY-FL-labeled catechol bisphosphate derivative 10 was incubated with the indicated proteins for 60 min before fluorescence polarization was analyzed. Changes in the fluorescence polarization values of 10 in the presence of protein are given as normalized fluorescence polarization values.
Ligand efficiencies (LE) were calculated using the following equation [4] LE = (-log 10 K i / N) where K i is the inhibitory constant (in mol/L) and N is the number of non-hydrogen atoms.
Molecular docking
The homology model of human STAT5b based on the amino acid sequence of human STAT5a has been described previously. [2] Docking experiments were performed with AutoDock Vina. [5] Default settings were used with the exception of the exhaustiveness, which was set to 50. The docking poses calculated by AutoDock Vina were visualized using PyMOL.
Tissue culture experiments
The full-length human STAT5a and STAT5b ORFs were PCR-amplified from K562 cDNA, and cloned into an expression vector based on pCS2 carrying a C-terminal GFP tag. K562 cells were cultured in RPMI 1640 medium (Invitrogen), containing 10% FBS (Gibco Life Technologies), 2 mM L-glutamine (PAA Laboratories) and penicillin/streptomycin (PAA Laboratories). Cells were transfected with either STAT5a-GFP or STAT5b-GFP plasmid using Fugene HD Transfection Reagent (Promega; 1 x 10 6 cells per well in 1 ml medium with a 4:1 ratio of Fugene:DNA). After 24 h, the transfected cells were treated with test compound or DMSO for 4 h (final DMSO concentration 0.2 %). Cells were subsequently harvested, and lysed with lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM Na 4 P 2 O 7 , 10% glycerol, 1% Triton X-100, 1 mM EDTA plus protease/phosphatase inhibitors 100 ng/ml aprotinin, 1 m Na 3 PO 4 , 10 mM NaF and 1 mM PMSF). The components of the cell lysates were separated by SDS-PAGE (10% polyacrylamide gel), then transferred to a nitrocellulose membrane using a semi-dry transfer apparatus. For each experiment, two gels and membranes were prepared. One membrane was probed with Stat5 antibodies (anti-pSTAT5, which recognizes Stat5a pTyr694 and STAT5b pTyr699, Cell Signaling; anti-total Stat5, Cell Signaling; anti--actin, Cell Signaling), the other membrane with anti-GFP (Cell Signaling, followed by anti--actin) to confirm even transfection. All primary antibodies are rabbit monoclonal antibodies. Membranes with bound primary antibody were incubated with -rabbit-HRP secondary antibody (Dako) and ECL was performed using Western Lightning Plus chemiluminescence reagent (PerkinElmer). Bands were visualized using an ImageQuant digital imaging system (GE Healthcare). Quantitative analysis was performed using ImageJ software (NIH). [6] General synthetic methods
Method 1: Benzyl phosphorylation of dihydroxy phenyl derivatives
To a stirred solution of aromatic diol (1 mmol) in dry acetonitrile (8 mL) was added CCl 4 (10 mmol), diisopropyl ethylamine (DIPEA) (4 mmol) and catalytic amounts of 4-(dimethylamino)pyridine (DMAP). Dibenzyl phosphite (DBP) (3 mmol) was added dropwise at 0 °C and maintained at these conditions for 0.5-1 h. Upon completion of the reaction, 3 mL of 0.5M KH 2 PO 4 were added. The reaction mixture was repeatedly extracted with ethyl acetate, and the combined organic phases were subsequently washed with 5% NaCl solution and H 2 O, and were dried over Na 2 SO 4 . The volatiles were removed under reduced pressure and purified by flash column chromatography. [7] Method 2: Debenzylation / Hydrogenolysis To a solution of benzyl-protected bisphosphate (1 mmol) in absolute ethanol (20 mL) was added 10% Pd/C (20-50 mg) under argon. The argon atmosphere was exchanged for a hydrogen atmosphere. After completion of the reaction (usually 1-2 h, reversed-phase TLC control), the mixture is filtered through celite and washed with ethanol. After removal of the solvent under reduced pressure, the product was dissolved in water and washed with dichloromethane (DCM) (2 x 5 mL). The product was isolated by lyophilization of the aqueous phase.
Method 3: Amide coupling reaction To a solution of carboxylic acid (1 mmol) in anhydrous DMF (10 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC-HCl) (1mmol) and 1-hydroxy benzotriazole hydrate (HOBt) (1 mmol) at 0 °C. The resulting suspension or clear solution was stirred for 30 min at 0 °C and for 1.5 h at room temperature. Triethylamine (3 mmol) and the corresponding primary/secondary amine (1 mmol) were added subsequently, and the mixture was stirred overnight at room temperature. After addition of water (100 mL), the mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with saturated aqueous NaHCO 3 solution, and dried over Na 2 SO 4 . After removal of the solvent under reduced pressure, the product was purified by flash column chromatography.
Method 4: Fmoc protection
The amine or amine hydrochloride (1 mmol) was dissolved in 2 mL of water. 2 mL of saturated aqueous NaHCO 3 was added at 0 °C. After 15 min, 9-fluorenyl-methoxycarbonyl chloride (Fmoc-Cl) (1.2 mmol in 3 mL CH 3 CN) was added and a white precipitate was formed. The reaction mixture was stirred at 0 °C for 1.5 h, and was then allowed to warm to room temperature. After 16 h, 10 mL of water and 5 mL of 1 M HCl were added. The mixture was extracted with ethyl acetate (3 x 20 ml). The combined organic phases were dried over Na 2 SO 4 and concentrated in vacuo. The product was purified by column chromatography.
Synthesis and spectroscopic characterization of compounds
1,2-Phenylene tetrabenzyl bis (phosphate) (1a)
1a was synthesized from catechol (200 mg, 1.8 mmol) according to Method 1. The crude product was purified by column chromatography in hexane / ethyl acetate (4:1 → 3:1) to afford pure product as colorless oil (1.03 g, 90%) . [7] R f = 0.33 (hexane / ethyl acetate 3:1); 1 H NMR (400 MHz, CDCl 3 ) δ=5. 09 -5.13 (m, 8H), 7.09 -7.11 (m, 2H), 7.23 -7. 38 (m, 22H) : = 3407, 2954, 2926, 2855, 2309, 1656, 1641, 1631, 1592, 1507, 1456, 1425, 1270, 1199, 1120, 1029, 978, 907, 638, 597, 510 , 487, 471, 459, 451, 404 
1,3-Phenylene tetrabenzyl bis(phosphate) (2a)
2a was synthesized from resorcinol (200 mg, 1.8 mmol) according to Method 1. The crude product was purified by column chromatography in hexane / ethyl acetate (4:1 → 3:1) and was obtained as colorless oil. Yield: 960 mg (86%). R f = 0.33 (hexane / ethyl acetate 3:1); 1 H NMR (400 MHz, CDCl 3 ) δ=5. 09 -5.11 (m, 8H), 7.00 -7.10 (m, 2H), 7.19 -7.21 (m, 1H), 7.33 -7.32 (m, 21H) ppm; 13 C NMR (101 MHz, CDCl 3 ) δ=70.21 (J=5.9), 112.71, 116.83 (d, J=4.4), 128.17, 128.73, 128.80, 130.38, 135.39 (d, J=7.3), 151.23 (d, J=6.6) (2) 2 was synthesized from 2a (370 mg, 0.59 mmol) according to Method 2 and was obtained as an off-white powder (158 mg, 95 %). [9] Melting point: 165-168 °C; 1 H NMR (300 MHz, DMSOd 6 ) δ = 6.93 -6.96 (m, 3H), 7.28 (t, J=7.4, 1H), 9.10 (bs, OH); 13 : = 3648, 3537, 3435, 2920, 2852, 2778, 2343, 2290, 1636, 1608, 1483, 1457, 1307, 1274, 1182, 1162, 1146, 1018, 906, 875, 812, 798, 776, 711, 682, 629, 539, 519, 505, 462, 454, 446 (1,2-Phenylenebis(methylene))bis(phosphonate) (3a)
1,2-bis(bromomethyl)benzene (2 g, 7.6 mmol) and triethylphosphite (3.13 ml, 16.7 mmol) were mixed and heated to 120 °C for 3 h. Volatiles were removed under reduced pressure and purified by column chromatography in DCM / MeOH (100:1 → 50:1) to afford 3a as white solid (2 g, 70%) . [10] [11] (1,2-Phenylenebis(methylene))bis(phosphonic acid) (3) 3a (0.5 g, 1.32 mmol) was dissolved in 3 M HCl (10 ml) and refluxed at 120 °C for 24 h. After completion of the reaction, volatiles were removed. The obtained solid was washed by refluxing in dichloromethane. After isolation of the product by filtration and removal of the solvent in vacuum, 3 was obtained as white crystals (0.273 g, 75%) [12] . CAS: 42104-58-5; 1 H NMR (400 MHz, DMSO-d 6 ) δ = 3. 15 (d, J=20.5, 4H), 7.04 -7.16 (m, 2H), 7.16 -7.27 (m, 2H), 9.24 (bs, 4H); 13 = 3456, 2967, 2936, 2852, 2803, 1630, 1605, 1497, 1454, 1262, 1258, 1215, 1181, 1171, 1128, 1092, 1070, 1052 , 997, 962, 947, 824, 778, 733, 598, 515, 472 , 429, 408 14.19, 22.74, 25.87, 29.22, 29.32, 29.35, 34.99, 36.91, 41.07, 115.32, 115.58, 120.45, 130.57, 143.35, 144.65, 174.56 ; UV/Vis: λ (nm) = 283, 204; IR (Film) : = 3480, 3339, 3186, 2950, 2925, 2854, 2726, 2643, 2413, 1842, 1660, 1602, 1555, 1530, 1455, 1443, 1384, 1281, 1254, 1222, 1193, 1150, 1114, 1062, 1048, 1027, 959, 940, 930, 922, 856, 814, 786, 757, 722, 664, 636, 616, 588, 560, 530, 489, 461, 452, 432, 407 14.22, 22.76, 25.85, 29.28, 29.45, 31.95, 35.17, 36.87, 40.39, 70.23 (dd, J=5.9, 3.0), 121.75 (d, J=2.3), 121.96 (d, J=2.3), 126.07, 128.09, 128.11, 128.67, 128.69, 128.72, 128.75, 135.46 (d, J=7.1), 137.31, 140.02 (t, J=6.6), 141.43 (t, J=6.5) 13.99, 22.10, 25.28, 28.61, 28.71, 28.77, 31.29, 34.62, 35.43, 121.87, 122.22, 124.52, 135.98, 140.88 (t, J=6.1), 142.34 (t, J=5.9), 160.65, 172.16 = 3412, 2923, 2853, 1692, 1659, 1651, 1643, 1632, 1614, 1555, 1513, 1505, 1384, 1069, 1034, 724, 597, 507, 497, 489, 467, 459, 445 (3,4-dihydroxyphenyl)-N,N-dioctylpropanamide 3-(3,4-dihydroxyphenyl) propanoate (5a) 3,4-Dihydroxyhydrocinnamic acid (hydrocaffeic acid) (300 mg, 1.7 mmol) was dissolved in anhydrous DMF (6 mL). The reaction was cooled down to 0 °C and 1-hydroxybenzotriazole hydrate (HOBt, 223 mg, 1.7 mmol) and N,N′-di-cyclohexylcarbodiimide (DCC, 1.7 mmol, 340 mg) were added to a stirred solution. After 1 h, dioctylamine (0.5 mL, 1.7 mmol) was added at 0 °C. After overnight reaction at room temperature, 10 mL of water was added. The reaction mixture was then extracted three times with 15 mL diethyl ether. The combined organic layers were washed with saturated NaHCO 3 solution, dried over Na 2 SO 4 and concentrated in vacuo. 2, 22.7, 22.8, 27.0, 27.2, 27.8, 29.1, 29.3, 29.4, 29.5, 31.5, 31.9, 35.2, 46.9, 48.7, 115.7, 119.9, 132.7, 143.2, 144.4, 173.3 ; UV/Vis: λ (nm) = 284, 212; IR (KBr) : = 3535, 3360, 2954, 2926, 2855, 2359, 1761, 1739, 1601, 1518, 1487, 1466, 1447, 1375, 1281, 1259, 1195, 1149, 1111, 1012, 954, 866, 810, 786, 721, 636, 590 3.22 -3.41 (m, 2H), 5.07 -5.12 (m, 8H), 6.96 (dd, J=8.5, 1.0, 1H), 7.15 -7.19 (m, 1H), 7.22 -7.30 (m, 21H) . 13 C NMR (101 MHz, cdcl 3 ) δ = 14.21, 22.75, 29.35, 29.47, 31.05, 31.90, 34.68, 70.19 (dd, J=5.9, 4.3), 121.65, 125.86, 128.08, 128.10, 128.66, 128.70, 135.51 (d, J=7.2), 139.61, 139.75 (t, J=6.5), 141.29 (t, J=6.5) : = 3065, 3034, 2954, 2926, 2855, 1736, 1642, 1592, 1510, 1456, 1425, 1380, 1288, 1214, 1154, 1122, 1081, 1036, 1015, 1000, 952, 886, 823, 740, 697, 639, 601, 500, 457 13.98, 22.09, 26.23, 27.34, 28.64, 30.36, 31.26, 33.93, 45.14, 47.10, 104.32, 122.59, 123.97, 137.69, 170.44; 31 = 3628, 3434, 2955, 2927, 2856, 2731, 2360, 2344, 2324, 1732, 1718, 1699, 1684, 1636, 1615, 1589, 1559, 1541, 1509, 1467, 1427, 1375, 1280, 1214, 1155, 1120, 984, 822, 723, 502 , 1H ), 7.32 (dd, J = 14.6, 9.8 Hz, 1H); 13 C NMR (100 MHz, CD 3 OD): δ = 25. 5, 26.9, 27.9, 44.5, 114.4, 116.5, 119.6, 121.2, 125.2, 130.0, 141.0, 145.0, 146.6, 147.8, 167.9 (9H-Fluoren-9-yl) methyl (3,4-dihydroxyphenethyl) carbamate (7a) 7a was synthesized from dopamine (1 g, 5.2 mmol) according to method 4. The crude material was purified by column chromatography (hexane/ethyl acetate 2:1) to obtain pure product 7a (1.5 g, 77%) [13] ; CAS: 248596-35-2. R f = 0.27 (hexane/ethyl acetate 2:1); 1 H NMR (400 MHz, DMSO-d 6 ) δ = 2.50 -2.56 (m, 2H), 3.11 (q, J=6.4 31, 38.87, 42.31, 109.70, 115.51, 116.03, 119.13, 119.99, 121.35, 127.26, 128.89, 130.28, 137.40, 139.39, 142.55, 143.50, 145.08, 157.44. (9H-Fluoren-9-yl)methyl (3,4-bis((bis(benzyloxy) 3320, 3089, 3064, 3034, 2951, 2895, 1720, 1607, 1591, 1509, 1477, 1454, 1425, 1382, 1281, 1251, 1214, 1151, 11235, 1106, 1080, 1015, 1000, 963, 8/89, 823, 741, 697, 640, 620 (9H-Fluoren-9-yl)methyl (3,4-bis(phosphonooxy)phenethyl)carbamate tetrasodium salt (7) 7b (250 mg, 0.28 mmol) was treated according to method 2. The obtained phosphoric acid (75 mg, 0.14 mmol) was dissolved in 3 ml H 2 O and mixed with an aqueous solution of NaHCO 3 (47 mg, 0.56 mmol). The clear solution was filtered through cotton (4 -6 cm in a glass pipette). The cotton was washed with 3-5 ml of H 2 O and lyophilized again to afford 7 as tetra sodium salt (77 mg, 88 %); Decomposition point: >250 °C charred without melting; 1 83, 40.75, 47.26, 66.16, 120.31, 120.48, 120.70, 122.46, 125.18, 127.61, 128.15, 130.30, 133.13, 141.10, 143.08 (t, J=6.1) : = 3751, 3735, 3404, 2212, 2146, 1696, 1583, 1508, 1478, 1449, 1422, 1338, 1278, 1221, 1122, 991, 967, 931, 879, 833, 818, 783, 760, 741, 703, 620, 593, 585, 567, 556, 504, 527, 499, 492, 477, 462, 443, 427, 413 
Methyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4-dihydroxyphenyl)propanoate (8a)
Fmoc-L-Dopa was obtained from commercially available L-Dopa (200mg, 1.0 mmol) according to method 4. This product was used without further purification. To the solution of Fmoc-LDopa (400 mg, 0.95 mmol) in 5 ml of dry DMF were added KHCO 3 (142 mg, 1.42 mmol) and methyl iodide (70 µl, 1.1 mmol), and the reaction was stirred for 4 h at room temperature. The crude product was purified by column chromatography in hexane / ethyl acetate (4:1 → 2:1) to obtain 8a as light brown oil (272 mg, 62% over 2 steps). 1 04, 46.58, 51.85, 55.95, 65.68, 115.36, 116.38, 119.80, 120.10, 125.23, 127.08, 127.63, 128.12, 140.69, 143.73, 143.91, 144.96, 155.89, 172.53 
Methyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4-bis((bis(benzyloxy)-phosphoryl) oxy)phenyl)propanoate (8b)
8b was produced from 8a (120 mg, 0.28 mmol) according to Method 1. Purification of the crude product by column chromatography in hexane/ethyl acetate (1:1) gave the product as a colorless oil (200 mg, 75%); R f = 0.37 (hexane/ethyl acetate 1:1); 1 H NMR (400 MHz, DMSOd 6 ) δ = 2.80 -3.08 (m, 2H), 3.62 (s, 3H), 4.10 -4.30 (m, 4H), 4.96 -5.23 (m, 8H), 7.11 (d, J=7.8, 1H), 7.18 -7.43 (m, 26H), 7.62 (t, J=7.5, 2H), 7.86 (d, J=7.5, 2H), 7.93 (d, J=8.2, 1H) ; 13 C NMR (101 MHz, DMSO-d 6 ) δ = 35. 56, 46.54, 51.99, 55.26, 65.67, 69.53 (t, J=5.5), 120.07, 121.02, 122.17, 125.14 (d, J=2.8), 126.67, 127.02, 127.59, 127.86, 127.93, 128.01, 128.37, 128.44, 128.48, 128.84, 129.45, 135.41 (dd, J=7.0, 3.2), 135.66, 139.68 (t, J=6.2), 140.52 (t, J=6.5), 143.62, 143.70, 155.91, 172 .00; 31 P NMR (162 MHz, DMSO-d 6 ) δ = -5.27 (s, 1P), -5.36 (s, 1P); UV/Vis: λ (nm) = 300, 289, 265, 217; IR (Film): = 3481, 3421, 3298, 3065, 3034, 2953 , 2897 , 2360 , 1722 , 1672 , 1654 , 1637 , 1594 , 1540 , 1509 , 1455 , 1428 , 1384 , 1280 , 12147, 1180 , 1158 , 1124 , 1081 , 1035 , 1018 , 1000 2955, 2926, 2854, 2360, 2338, 1705, 1671, 1634, 1509, 1449, 1427, 1385, 1338, 1279, 1252, 1217, 1158, 1123, 1081, 953, 906, 760, 741, 699, 621, 572, 534, 512 Synthesis of (9H-Fluoren-9-yl) methyl 3,4-dihydroxybenzylcarbamate (9a) (4-(Aminomethyl)benzene-1,2-diol hydrobromide (200 mg, 0.9 mmol) was dissolved in 2 mL of water, and 2 ml of saturated NaHCO 3 was added at 0 °C. After 15 min, 9-fluorenylmethoxycarbonyl chloride (Fmoc-Cl) (282 mg, 1.1 mmol, in 3 ml CH 3 CN) was added and a white precipitate was formed. The reaction mixture was stirred at 0 °C for 1.5 h and then stirred at room temperature for an additional 16 h. After completion of the reaction, 10 mL of water and 5 mL of 1M HCl were added. The mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated in vacuo. The product was purified by column chromatography in DCM/methanol (50:1) to afford 9a as oil (160 mg 7, 47.4, 66.9, 114.9, 115.3, 119.5, 120.1, 125.2, 127.2, 127.8, 130.5, 141.4, 144.1, 157.2 ; UV/Vis: λ (nm) = 300, 288, 265, 211; IR (KBr : = 3424, 2925 , 2953 , 1694 , 1646 , 1635 , 1523 , 1449 , 1384 , 1264 , 1129 , 1114 30, 47.40, 66.86, 70.28 (dd, J = 5.8, 3.4),120.11, 120.88 (d, J=2.3), 121.94 (d, J=1.9), 125.12, 127.20, 127.83, 128.11, 128.15, 128.67, 128.73, 135.45 (d, J=7.1), 136.49, 140.74 (t, J=6.5), 141.46, 143.98, 156.40; 31 3313, 3089, 3065, 3034, 2953, 2895, 2360, 2342, 2323, 1721, 1654, 1607, 1594, 1538, 1510, 1477, 1455, 1428, 1383, 1357, 1281, 1214, 1158, 1122, 1081, 1017, 1000, 884, 822, 759, 741, 697, 620, 602, 511, 500, 492, 459, 426 (9H-Fluoren-9-yl) methyl (3,4-bis(phosphonooxy)benzyl)carbamate (9) 9 was produced from 9b (170 mg, 0.19 mmol) according to Method 2 as pale yellow powder (100 mg, 75%); Melting point: 132-133 °C; 1 H NMR (400 MHz, DMSO-d 6 ) δ = 4.12 (d, J=6.1, 2H), 4.25 (t, J=7.0, 1H), 4.33 (d, J=7.0, 2H), 6.92 (d, J=8.5, 1H), 7.20 (s, 2H), 7.35 (q, J=8.0, 7.5, 2H), 7.42 (q, J=5.9, 4.3, 2H), 7.71 (d, J=7.5, 2H), 7.90 (d, J=7.5, 3H), 8.16 (s, 1H); 13 C NMR (101 MHz, DMSO-d 6 ) δ = 43. 21, 46.73, 65.44, 120.07, 121.41, 122.39, 122.75, 125.19, 127.07, 127.58, 135.90, 140.71, 143.87, 156.28; 31 P NMR (162 MHz, CD 3 OD) δ = -3.15 (s); UV/Vis: λ (nm) = 300, 289, 265, 210; IR (KBr : = 3423, 3067, 3019, 2958 , 2926 , 2892 , 1693 , 1646 , 1595 , 1543 , 1510 , 1449 , 1429 , 1284 , 1272 , 1214 , 1161 , 1120 ; HRMS (ESI) C 22 H 20 NO 10 P 2 calcd: 520.0568 [M-H + ], found: 520.0563. 3, 7, ,5λ 4 
Synthesis of 10a was carried out in a variation of the published procedure. [14] To a solution of 2,4-dimethyl-1H-pyrrole (1.84 g, 19.3 mmol) in dry DCM (40 mL), methyl 8-chloro-8-oxooctanoate (2 g, 9.67 mmol) was added dropwise over a period of 10 min at room temperature. The deep red solution was refluxed for 4 h and poured into hexane (50 mL). After cooling, the solvent was evaporated in vacuo. The solid was dissolved in dry DCM (20 mL), triethylamine was added (2.7 mL, 19.3 mmol) , and the solution was stirred for 15 min at room temperature. Subsequently, BF 3 -Et 2 O (5.48 mL, 38.6 mmol) was added dropwise, and the mixture was stirred for 2 h at room temperature. The deep red solution was poured into sat. NaHCO 3 solution. The organic phase was separated, washed with saturated aqueous Na 2 CO 3 solution, and dried over Na 2 SO 4 . After removal of the solvent under reduced pressure and column chromatography in hexane/DCM (4:1 → 1:1 → 2:3), 10a is obtained as an orangegreen fluorescing solid (2 g, 50%) . [14] [15] 14.57, 16.51, 24.99, 28.50, 29.08, 30.17, 31.86, 34.06, 51.64, 121.72, 131.54, 140.38, 146.51, 153.91, 165.97, 174.14; 19 F NMR (282 MHz, CDCl 3 ) δ = -147.10 (dd, J=65.2, 31.6); UV/Vis: λ (nm) = 495, 358, 304, 241; IR (KBr): = 3448, 2931, 2867, 2857, 1735, 1640, 1552, 1535, 1510, 1474, 1464, 1447, 1433, 1408, 1370, 1324, 1307, 1276, 1250, 1225, 1205, 1162, 1112, 1082, 1060, 1023, 988, 838, 810, 730, 716, 581, 514, 482 7-(5,5-Difluoro-1,3,7,9-tetramethyl-5H-4λ 4 ,5λ 4 
Synthesis of 10b was carried out essentially as described. [14] To the solution of 10a (300 mg, 0.77 mmol) in isopropanol (10 mL), an aqueous solution of 0.1 M KOH was added dropwise at 0 ºC, and the mixture was stirred for 2 h at room temperature. The solution was diluted with 100 mL of water and acidified with 1 N HCl to pH = 1.5. The solution was extracted with ethyl acetate (3 x 30 mL), and the combined organic phases were dried over Na 2 SO 4 . After removal of the solvent under reduced pressure and column chromatography (hexane / ethyl acetate 3:2), 10b was obtained as an orange solid (287 mg, 99%) [14] 14.58, 16.53, 24.72, 28.48, 28.98, 30.13, 31.83, 33.94, 121.75, 131.56, 140.38, 146.46, 153.97, 165.97, 179.26; 19 F NMR (376 MHz, CDCl 3 -147.18 --146.80 (m) ; UV/Vis: λ (nm) = 495, 355, 305, 241; IR (KBr): = 3651, 3434, 2929 , 2864 , 1737 , 1709 , 1631 , 1551 , 1510 , 1475 , 1440 , 1409 , 1372 , 1308 , 1225 , 1161 , 1114 , 1081 , 1028 3, 7, ,5λ 4 -dipyrrolo [1,2-c:2',1'-f] [1, 3, 2] diazaborinin-10-yl)-N- (3,4-dihydroxybenzyl) 4.06 (d, J=5.8, 2H), 6.23 (s, 2H), 6.47 (dd, J=8.0, 2.0, 1H), 6.63 (dd, J=5.1, 2.9, 2H), 8.11 (t, J=5.8, 1H), 8.77 (s, 2H) ; 13 C NMR (101 MHz, DMSO-d 6 ) δ = 14.07, 15.85, 25.26, 27.75, 28.32, 29.47, 31.29, 35.27, 41.67, 114.93, 115.20, 118.13, 121.65, 130.51, 130.70, 140.75, 144.06, 145.05, 146.85, 152.98, 171.72; 19 F NMR (376 MHz, DMSO-d 6 ) δ = -145.62 --142.53 (m); UV/Vis: λ (nm) = 495, 358, 305, 291, 236, 203; IR (KBr): = 3424, 2926 , 2860 , 1639 , 1550 , 1510 , 1474 , 1445 , 1409 , 1371 , 1308 , 1289 , 1274 , 1226 , 1202 , 1161 , 1115 , 1080 , 1026 Tetrabenzyl (4-((7-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ 4 ,5λ 4 -dipyrrolo [1,2-c:2',1'-f] [1, 3, 2] diazaborinin-10-yl)heptanamido)methyl)-1,2-phenylene) bis(phosphate) (10d) 1.30 (dt, J=8.2, 5.2, 2H), 6H), 2.11 (t, J=7.3, 2H), 2.37 (s, 12H), 2.88 (dd, J=10.9, 5.5, 2H), 4.20 (d, J=5.9, 2H), 8H), 6.19 (s, 2H), 7.07 (dd, J=8.4, 1.9, 1H), 21H), 8.35 (t, J=6.0, 1H); 13 C NMR (100 MHz, 16.28, 25.66, 28.22, 28.82, 29.95, 31.66, 35.74, 41.65, 70.01 (dd, J=5.5, 2.3), 120.55, 121.73, 122.10, 124.96, 128.34 (d, J=2.2), 128.93, 128.96, 131.20, 135.88 (dd, J=7.0, 2.5), 138.63, 140.06 (t, J=6.4), 141.19, 141.27, 141.33, 147.27, 153.43, 172.67; 19 4-((7-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ 4 ,5λ 4 -dipyrrolo [1,2-c:2',1'- 14.05, 15.85, 25.16, 27.76, 28.36, 29.43, 31.27, 35.24, 41.38, 122.43, 122.76, 130.69, 135.74, 140.76, 142.09 -142.43 (m), 143.16 -143.45 (m), 146.84, 152.96, 171.98; 31 -144.22 (dd, J=61.9, 27.8) ; UV/Vis: λ (nm) = 529, 492, 339, 306, 276, 207, 202; IR (KBr): = 3442, 2927 , 2857 , 1640 , 1551 , 1509 , 1431 , 1383 , 1305 , 1284 , 1200 , 1160 , 1084 , 1023 6.87 (t, J=5.9, 1H), 6.97 (dd, J=8.4, 1.5, 1H), 7.13 -7.31 (m, 21H), 7.31 -7.41 (m, 1H), 7.42 -7.55 (m, 3H), 7.69 -7.88 (m, 1H), 8.04 -8.22 (m, 1H); 13 C NMR (101 MHz, CDCl 3 ) δ = 42. 21, 68.04, 70.29 (dd, J=5.8, 3.5), 105.99, 121.04 (d, J=2.4), 121.99 (d, J=2.4), 122.00, 122.14, 124.84, 125.28, 125.84, 126.02, 126.89, 127.92, 128.12 (d, J=2.2), 128.66, 128.67, 128.72, 134.74, 135.39, 135.46, 135.90, 140.84 (t, J=6.5) 106.18, 119.79 (d, J=2.4), 120.46 (d, J=2.3), 120.75, 121.63, 121.68, 124.95, 126.09, 126.31, 127.10, 127.77, 131.25, 134.40, 143.93 (t, J=5.9) 1661, 1598, 1582, 1542, 1509, 1463, 1427, 1398, 1385, 1353, 1282, 1269, 1240, 1228, 1109, 991, 958, 878, 834, 812, 795, 771, 703, 657, 571, 539, 530, 503, 496, 457, 443, 429 52, 67.04, 107.27, 115.02, 115.25, 118.25, 118.68, 123.84, 126.46, 126.74, 127.50, 128.73, 129.31, 130.10, 134.03, 144.16, 145.06, 155.59, 167.25 107.33, 118.63, 120.33 -120.40 (m), 121.22, 123.87, 124.63, 126.46, 126.74, 127.49, 127.86, 128.00, 128.45, 128.48, 128.75, 129.34, 134.01, 135.41 (d, J=7.0, 1.0), 137.62, 139.69 (t, J=6.4) 6.90 -7.02 (m, 1H), 7.08 -7.39 (m, 4H), 7.45 (t, J=7.5, 1H), 7.68 -7.95 (m, 3H), 8.73 (d, J=6.2, 1H) ; 13 C NMR (101 MHz, DMSO-d 6 ) δ = 41. 31, 67.03, 107.32, 118.69, 121.56, 122.25, 123.13, 123.88, 126.50, 126.80, 127.52, 128.76, 129.36, 134.05, 135.59, 155.59, 167.61; 31 = 3409, 3558, 2924, 2853, 2715, 2332, 1648, 1630, 1600, 1552, 1510, 1468, 1429, 1392, 1350, 1270, 1258, 1218, 1182, 1157 , 1122, 1017, 980, 915, 839, 813, 748, 726, 708, 622, 580, 505, 497, 472, 426 14.04, 60.73, 64.76, 107.19, 119.15, 125.89, 126.37, 126.95, 127.77, 130.27, 131.03, 136.32, 157.25, 160.61, 167.53, 168.41 ; UV/Vis: λ (nm) = 293, 242, 236, 214; IR (KBr) : = 3647, 3583, 3564, 3544, 3523, 3501, 3484, 3463, 3448, 3062, 2980, 2909, 2868, 2676, 2629, 2561, 1766, 1693, 1630, 1580, 1504, 1482, 1441, 1415, 1389, 1341, 1301, 1261, 1201, 1174, 1131, 1081, 1028, 928, 913, 852, 822, 766, 749, 698, 604, 562, 471 14.32, 61.71, 65.53, 107.08, 119.89, 120.36, 124.46, 124.64, 127.48, 127.68, 128.59, 129.24, 130.59, 130.97, 136.19, 138.21, 157.49, 165.85, 168.66 ; UV/Vis: λ (nm) = 279, 248, 240; IR (KBr) : = 3646, 3564, 3545, 3523, 3499, 3447, 3262, 3195, 3136, 3065, 2983, 2924, 1758, 1717, 1641, 1602, 1547, 1501, 1481, 1442, 1392, 1335, 1305, 1276, 1241, 1203, 1172, 1132, 1098, 1077, 1021, 965, 952, 912, 892, 862, 844, 821, 752, 716, 694, 601, 593, 533, 507, 475 2-((6-(Phenylcarbamoyl) naphthalen-2-yl)oxy)acetic acid (13e)
To a solution of 13d (0.55 g, 1.57 mmol) in THF (5 ml), an aqueous solution of 1 M NaOH (5 mL) was added dropwise, and the reaction was stirred at room temperature for 1 h. The reaction was diluted with 50 mL water and acidified to pH 1-2 by addition of 1 N HCl. After extraction of the product with ethyl acetate (3 x 50 ml) and removal of the solvent under reduced pressure, 13e was obtained as a white solid (0.5 g, 99%); Melting point: 212 -215 °C; 1 H NMR (400 MHz, DMSO-d 6 ) δ = 4.83 (s, 2H), 7.09 (tt, J=7.4, 1.2, 1H), 7.29 (dd, J=8.9, 2.5, 1H), 7.32 -7.40 (m, 3H), 7.76 -7.85 (m, 2H), 7.90 (d, J=8.7, 1H), 7.95 -8.04 (m, 2H), 8.50 (d, J=1.9, 1H) , 10.32 (s, 1H), 13.05 (s, 1H); 13 C NMR (75 MHz, DMSO-d 6 ) δ = 64. 60, 106.98, 119.34, 120.33, 123.54, 125.02, 126.83, 127.59, 127.83, 128.59, 130.12, 130.64, 7, 70.11 (d, J=5.9), 119.93 (d, J=2.3), 125.3, 125.59 (d, J=7.4), 128.1, 128.2, 128.3, 128.86 (d, J=1.3), 128.7, 128.9, 128.9, 131.6, 135.55 (d, J=7.0), 135.9, 149.15 (d, J=6.7) 
